Association sclérose en plaques et thrombopénie auto-immune

Graníer, H.; Bellard, S.; Nicolás, Xavier; Laborde, Julien; Talarmin, F.

doi:10.1016/s0248-8663(01)00502-1

Cited by 7 publications

(2 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, review of the available literature has identified additional MS patients with ITP complicating their illness. Granier et al in 2001 reported a 40 year old French patient with well-documented MS who had a transient thrombocytopenia [ 36 ]. Four additional cases have been identified recently in Spain [ 37 ].…”

Section: Discussionmentioning

confidence: 99%

Evidence of platelet activation in multiple sclerosis

Sheremata

Horstman

et al. 2008

J Neuroinflammation

162

121

View full text Add to dashboard Cite

Objective: A fatality in one multiple sclerosis (MS) patient due to acute idiopathic thrombocytopenic purpura (ITP) and a near fatality in another stimulated our interest in platelet function abnormalities in MS. Previously, we presented evidence of platelet activation in a small cohort of treatment-naive MS patients. Methods:In this report, 92 normal controls and 33 stable, untreated MS patients were studied. Platelet counts, measures of platelet activation [plasma platelet microparticles (PMP), P-selectin expression (CD62p), circulating platelet microaggragtes (PAg)], as well as platelet-associated IgG/ IgM, were carried out. In addition, plasma protein S activity was measured.Results: Compared to controls, PMP were significantly elevated in MS (p < 0.001) and CD62p expression was also markedly elevated (p < 0.001). Both are markers of platelet activation. Plateletassociated IgM, but not IgG, was marginally elevated in MS (p = 0.01). Protein S in MS patients did not differ significantly from normal values. Conclusion:Platelets are significantly activated in MS patients. The mechanisms underlying this activation and its significance to MS are unknown. Additional study of platelet activation and function in MS patients is warranted.

show abstract

Section: Discussionmentioning

confidence: 99%

Evidence of platelet activation in multiple sclerosis

Sheremata

Horstman

et al. 2008

J Neuroinflammation

162

121

View full text Add to dashboard Cite

show abstract

“…In the 1950's-60's, at least ten studies appeared on the relation of platelets to CNS demyelination, several of which reported augmented platelet adhesiveness in MS, which correlated with disease activity [298-301]. More recently, a number of observations of platelet abnormalities in MS patients have appeared [302-304], and others cited below. We became interested when colleague W. Sheremata encountered MS patients with severe immune thrombocytopenic purpura (ITP) [305], leading to our report of increased platelet microparticles and platelet activation marker CD62P (P-Selectin) in MS [306].…”

Section: Platelets In Multiple Sclerosis: Smoking Gun?mentioning

confidence: 99%

Role of platelets in neuroinflammation: a wide-angle perspective

Horstman

Ahn

et al. 2010

J Neuroinflammation

101

View full text Add to dashboard Cite

ObjectivesThis review summarizes recent developments in platelet biology relevant to neuroinflammatory disorders. Multiple sclerosis (MS) is taken as the "Poster Child" of these disorders but the implications are wide. The role of platelets in inflammation is well appreciated in the cardiovascular and cancer research communities but appears to be relatively neglected in neurological research.OrganizationAfter a brief introduction to platelets, topics covered include the matrix metalloproteinases, platelet chemokines, cytokines and growth factors, the recent finding of platelet PPAR receptors and Toll-like receptors, complement, bioactive lipids, and other agents/functions likely to be relevant in neuroinflammatory diseases. Each section cites literature linking the topic to areas of active research in MS or other disorders, including especially Alzheimer's disease.ConclusionThe final section summarizes evidence of platelet involvement in MS. The general conclusion is that platelets may be key players in MS and related disorders, and warrant more attention in neurological research.

show abstract

Alemtuzumab als neue Therapieoption der Multiplen Sklerose

Warnke

Zettl

et al. 2009

Nervenarzt

View full text Add to dashboard Cite

Monoclonal antibodies are of growing interest as treatment options for immune-mediated diseases in neurology. As our knowledge of immunological principals increases, we learn to modulate specifically mechanisms of pathogenesis by the use of monoclonal antibodies. It is clearly desirable to improve efficacy in disease treatment without increasing toxicity by using drugs with more specific modes of action. Natalizumab was the first monoclonal antibody approved in the field of neurology for treatment of relapsing remitting multiple sclerosis (MS). Several other monoclonal antibodies are currently under investigation. Alemtuzumab, a monoclonal antibody targeting CD52, is a highly promising agent currently being studied in two phase III clinical trials. In this review, data from the recently published phase II clinical trial in the treatment of early relapsing remitting MS is summarized and analyzed in light of the development of alemtuzumab for MS and its potential role in treating this disease is discussed.

show abstract

Association sclérose en plaques et thrombopénie auto-immune

Cited by 7 publications

References 5 publications

Evidence of platelet activation in multiple sclerosis

Evidence of platelet activation in multiple sclerosis

Role of platelets in neuroinflammation: a wide-angle perspective

Alemtuzumab als neue Therapieoption der Multiplen Sklerose

Contact Info

Product

Resources

About